NYT picks apart ADHD

Share this article:

The New York Times gives a clinical and marketing look at the uptick in the $9-billion dollar attention deficit disorder market. Among the topics covered are the nomenclature for one of the condition's hallmark drugs—Adderall, which was a combination of A.D.D. and All—and the professional and consumer marketing strategies that have helped cultivate a prescriptive landscape that psychiatrist Keith Conners tells the Gray Lady “make it look like an epidemic. Well, it's not. It's preposterous.”

The piece also touches on the prickly topic of pharmaceutical-sponsored speaking engagements (one industry-compensated orator says company money has not influenced his research) and patient-facing materials about ADHD surfacing in at least one school system as well as the relatively recent wave of adult ADHD awareness messaging, among other topics.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Massachusetts painkiller ban overruled

A District Court says Massachusetts cannot ban opioid painkiller Zohydro.

Ranbaxy extends branded Diovan's life

Ranbaxy may be on the blocks, but it has a hold on the right to produce generics of the Novartis heart medication Diovan. Only problem: it can't, and that is good news for Novartis.

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.